HypertensionWONDeRNCT01362283
Epidemiologic Study to Evaluate the Proportion of Cardiovascular Disease Risk Factors in Korean Hypertensive Patients
An observational study of Hypertension, run by GlaxoSmithKline.
Trial summary
The purpose of this study is investigating the proportion of Cardiovascular disease risk factors of hypertensive patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hypertension
- What is being tested?
- Blood Sampling
- How many people
- 3,109 participants
- Where
- No sites listed yet
- Study dates
- Aug 2010to Jan 2011
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Korea, Diagnosed hypertensive patient
Who may be able to join
- Essential hypertensive patient no less than 18 yeas old
- Patient who gave informed consent form
Who cannot join
- Patient was diagnosed as secondary hypertension
- Patient who have white-coat hypertension
About this study
Official title: A Multi-center, Observational, Cross-sectional Study to Evaluate CVD Risk Factors in Korean Hypertensive Patients
The purpose of this study is investigating the proportion of Cardiovascular disease risk factors of hypertensive patients.
Read the detailed description
Primary endpoint: To evaluate the Proportion of patients with Cardiovascular disease high risk factors
Secondary endpoint: To evaluate the Proportion of patients with Cardiovascular disease risk factors, To evaluate the Proportion of patients with Cardiovascular disease, To evaluate Target blood pressure achievement rate according to the proportion of Cardiovascular disease risks
- Conditions
- Hypertension
- Being tested
- Blood Sampling
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood SamplingOther
Also called Blood sampling for cardiovascular disease risk
Blood sampling for Fasting Plasma Glucose, Hemoglobin A1C, Cholesterols, Blood Urea Nitrogen, Creatinine
| Study group | Role | What they receive |
|---|---|---|
| Hypertension | Subject who meet eligible criteria Receives: Other: Blood Sampling |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of patients with cardiovascular disease high risk factors
Between patients with essential hypertension
Measured: 6years, average duration of hypertension
Secondary outcomes (3)
Proportion of patients with Cardiovascular disease risk factors
Between patients with essential hypertension
Measured: 6years, average duration of hypertension
Proportion of patients with Cardiovascular disease
Between patients with essential hypertension
Measured: 6years, average duration of hypertension
Target Blood Pressure achievement rate according to the proportion of Cardiovascular disease risks
Between patients with essential hypertension
Measured: 6years, average duration of hypertension
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 May 2011 (estimated)
- Study startAug 2010
- Primary completionJan 2011
- Study completionJan 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypertensionStudies of the same condition, open and under way.
- More trials run by GlaxoSmithKlineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Cross-sectional
- Enrolment
- 3,109 participants (actual)
Sponsor and investigators
- Lead sponsor
- GlaxoSmithKline
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- GSK Clinical Trials, Study director, GlaxoSmithKline
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01362283
- Sponsor's protocol ID
- 114619
- Acronym
- WONDeR
- Status last verified
- Nov 2016
- First submitted
- 5 May 2011
- Last updated
- 1 Dec 2016
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Dec 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-center, Observational, Cross-sectional Study to Evaluate CVD Risk Factors in Korean Hypertensive Patients
- ClinicalTrials.gov ID
- NCT01362283
- Acronym / sponsor ID
- WONDeR / 114619
- Conditions
- Hypertension
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 3,109 participants (actual)
- Lead sponsor
- GlaxoSmithKlineIndustry (pharma, biotech, devices)
- Study start
- Aug 2010
- Primary completion
- Jan 2011 (actual)
- Study completion
- Jan 2011 (actual)
- First posted
- 30 May 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is investigating the proportion of Cardiovascular disease risk factors of hypertensive patients.
Detailed description
Primary endpoint: To evaluate the Proportion of patients with Cardiovascular disease high risk factors
Secondary endpoint: To evaluate the Proportion of patients with Cardiovascular disease risk factors, To evaluate the Proportion of patients with Cardiovascular disease, To evaluate Target blood pressure achievement rate according to the proportion of Cardiovascular disease risks
Study design
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Hypertension | – | Other: Blood SamplingSubject who meet eligible criteria |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Korea, Diagnosed hypertensive patient
Key inclusion criteria (2 listed)
- Essential hypertensive patient no less than 18 yeas old
- Patient who gave informed consent form
Key exclusion criteria (2 listed)
- Patient was diagnosed as secondary hypertension
- Patient who have white-coat hypertension
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood SamplingAlso: Blood sampling for cardiovascular disease riskBlood sampling for Fasting Plasma Glucose, Hemoglobin A1C, Cholesterols, Blood Urea Nitrogen, Creatinine | Other | Hypertension |
Primary outcome
Proportion of patients with cardiovascular disease high risk factors
Time frame: 6years, average duration of hypertension
Between patients with essential hypertension
3 secondary outcomes
Proportion of patients with Cardiovascular disease risk factors
Time frame: 6years, average duration of hypertension
Proportion of patients with Cardiovascular disease
Time frame: 6years, average duration of hypertension
Target Blood Pressure achievement rate according to the proportion of Cardiovascular disease risks
Time frame: 6years, average duration of hypertension
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Dec 2016.
Related trials for Hypertension
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
RecruitingObservational study
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
Pulmonary Disease, Pulmonary Hypertension
Recruiting
Trauma-informed Approach to Timely Detection and Management of Early Postpartum Hypertension
Postpartum Hypertension
Active, not recruitingPhase 1
Study of Intravenous ZMA001 in Healthy Subjects
Pulmonary Arterial Hypertension PAH
Recruiting
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Heart Failure, Heart Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
GSK Clinical Trials study director
GlaxoSmithKline
Questions about this trial
What is this clinical trial studying?
An observational study of Hypertension, run by GlaxoSmithKline.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Dec 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of patients with cardiovascular disease high risk factors (time frame: 6years, average duration of hypertension). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Dec 2016; AzTrials last refreshed its copy on 6 Nov 2026.